CA2442049C - Ablation selective des neurones detectant la douleur par l'administration d'un recepteur de vanilloide - Google Patents

Ablation selective des neurones detectant la douleur par l'administration d'un recepteur de vanilloide Download PDF

Info

Publication number
CA2442049C
CA2442049C CA2442049A CA2442049A CA2442049C CA 2442049 C CA2442049 C CA 2442049C CA 2442049 A CA2442049 A CA 2442049A CA 2442049 A CA2442049 A CA 2442049A CA 2442049 C CA2442049 C CA 2442049C
Authority
CA
Canada
Prior art keywords
ganglion
composition
agonist
pain
vanilloid receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2442049A
Other languages
English (en)
Other versions
CA2442049A1 (fr
Inventor
Michael J. Iadarola
Zoltan Olah
Laszlo Karai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CA2442049A1 publication Critical patent/CA2442049A1/fr
Application granted granted Critical
Publication of CA2442049C publication Critical patent/CA2442049C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des méthodes et des nécessaires servant à l'ablation sélective de neurones de sensibilité à la douleur. Ces méthodes consistent à administrer un agoniste du récepteur de vanilloïde à un ganglion, en quantité suffisante pour provoquer la mort des neurones porteuses du récepteur de vanilloïde. La présente invention concerne donc des méthodes pour maîtriser la douleur et les troubles inflammatoires impliquant l'activation de neurones porteuses du récepteur de vanilloïde.
CA2442049A 2001-03-22 2001-03-22 Ablation selective des neurones detectant la douleur par l'administration d'un recepteur de vanilloide Expired - Lifetime CA2442049C (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/009425 WO2002076444A1 (fr) 2001-03-22 2001-03-22 Neurochirurgie moleculaire par administration locale de capsicine ou de resiniferatoxine destinee a maitriser la douleur

Publications (2)

Publication Number Publication Date
CA2442049A1 CA2442049A1 (fr) 2002-10-03
CA2442049C true CA2442049C (fr) 2010-06-01

Family

ID=21742435

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2442049A Expired - Lifetime CA2442049C (fr) 2001-03-22 2001-03-22 Ablation selective des neurones detectant la douleur par l'administration d'un recepteur de vanilloide

Country Status (2)

Country Link
CA (1) CA2442049C (fr)
WO (1) WO2002076444A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2562025T3 (es) 2002-12-18 2016-03-02 Centrexion Therapeutics Corporation Administración de capsaicinoides para el tratamiento de la artrosis
DK1838301T3 (en) 2004-12-28 2015-04-27 Mestex Ag Use of resiniferate toxin (RTX) for the preparation of a pain management agent
EP3534961A4 (fr) 2016-11-02 2020-05-27 Centrexion Therapeutics Corporation Formulations injectables aqueuses stables de capsaïcine et leurs utilisations médicales
IL272036B1 (en) 2017-07-20 2024-09-01 Centrexion Therapeutics Corp Methods and compositions for treating pain using capsaicin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014083A1 (fr) * 1989-05-15 1990-11-29 Afferon Corporation Composition et procede de desensibilisation neurale
AU5460598A (en) * 1996-11-15 1998-06-03 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Pharmaceutical compositions containing vanilloid agonists in combination with vanilloid antagonists
CN1210254C (zh) * 1999-02-22 2005-07-13 株式会社太平洋 作为有效的香草类受体激动剂和镇痛药的含有树脂毒素药效基团的香草类类似物,其组合物以及应用

Also Published As

Publication number Publication date
CA2442049A1 (fr) 2002-10-03
WO2002076444A1 (fr) 2002-10-03

Similar Documents

Publication Publication Date Title
US9827223B2 (en) Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agonist
Mitsi et al. Modulation of pain, nociception, and analgesia by the brain reward center
Sladky et al. Analgesic efficacy and respiratory effects of butorphanol and morphine in turtles
Tai et al. Amitriptyline suppresses neuroinflammation and up-regulates glutamate transporters in morphine-tolerant rats
Adrian et al. Chronic maladaptive pain in cats: a review of current and future drug treatment options
US9216171B2 (en) Methods of preventing ischemic injury using peripheral nociceptive stimulation
US20030104085A1 (en) Methods and compositions for treating back pain
Xu et al. Identification of a glutamatergic claustrum-anterior cingulate cortex circuit for visceral pain processing
Bisetto et al. Evaluation of sedative and antinociceptive effects of dexmedetomidine, midazolam and dexmedetomidine–midazolam in tegus (Salvator merianae)
Bishop et al. Combined intrastriatal dopamine D1 and serotonin 5-HT2 receptor stimulation reveals a mechanism for hyperlocomotion in 6-hydroxydopamine-lesioned rats
Zhuo et al. Modulation of noxious and non-noxious spinal mechanical transmission from the rostral medial medulla in the rat
Peng et al. Inhibition of neuronal Na+ currents by lacosamide: Differential binding affinity and kinetics to different inactivated states
WO2012060845A1 (fr) Méthodes pour prévenir la lésion ischémique par une stimulation nociceptive périphérique
CA2442049C (fr) Ablation selective des neurones detectant la douleur par l'administration d'un recepteur de vanilloide
Uhelski et al. Topical application of loperamide/oxymorphindole, mu and delta opioid receptor agonists, reduces sensitization of C-fiber nociceptors that possess NaV1. 8
EP3468602B1 (fr) Inhibiteur du récepteur flt3 à faible dose pour le traitement d'une douleur neuropathique
Baggio et al. Sex differences in carbamazepine effects in a rat model of trigeminal neuropathic pain
ES2808667T3 (es) Derivados de diarilmetilideno piperidina y su uso como agonistas del receptor opioide delta
Adler Laboratory evaluation of antiepileptic drugs
BR102014010268B1 (pt) Uso do peptídeo sintético pntx-19 para tratamento de dor
US20240165129A1 (en) Methods of treating pain and depression
Uthirapathy Study comparing the effects of different anesthetic drugs used during clinical anesthesia in Koi Fish
Frajmund Functional Effects of the Relaxin-3/RXFP-3 Pathway on the Affective Dimension of Chronic Pain
Lucas et al. RNA-DEPENENT PROTEIN KINASE MEDIATES OPIOID-INDUCED HYPERALGESIA
Micheal et al. SELECTIVITY TO PERIODIC SEQUENCES OF SOUND IN AUDITORY CORTICAL SINGLE NEURONS

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20210322